Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Trends Cancer. 2017 Jan;3(1):39–55. doi: 10.1016/j.trecan.2016.11.006

Table 2.

Cell cycle proteins that could be associated with response to CDK4/6 inhibition

ACCEPTED RESISTANCE RELEVANT TUMOR TYPES REFERENCES
RB loss Multiple [55–58, 81, 92, 125]
p16INK4a high RB-deficient tumors or HPV [55–58, 130]
Viral oncoproteins of DNA tumor viruses Cervical Cancer and SSCHN [56, 90]
PUTATIVE RESISTANCE RELEVANT TUMOR TYPES
Cyclin E overexpression (Cyclin E1/E2 amplification) Uterine (40%), Ovarian (20%), Bladder (15%) Metastatic prostate cancer (20%), Breast (15%) [60, 71]
E2F overexpression (E2F3 amplification) Bladder (30%), [55, 56]
PUTATIVE SENSITIVITY RELEVANT TUMOR TYPES
Cyclin D1 amplification/translocation MCL, Breast, Esophageal [58, 113]
CDK4 amplification Liposarcoma, GBM [81, 82]
CDKN2A loss Multiple [135]